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Mutations in the leucine-rich repeat kinase 2 gene are the most common cause of
autosomal dominant Parkinson’s disease (PD). To assess the cerebrospinal fluid (CSF)
levels of α-synuclein oligomers in symptomatic and asymptomatic leucine-rich repeat
kinase 2 mutation carriers, we used enzyme-linked immunosorbent assays (ELISA) to
investigate total and oligomeric forms of α-synuclein in CSF samples. The CSF samples
were collected from 33 Norwegian individuals with leucine-rich repeat kinase 2 mutations:
13 patients were clinically diagnosed with PD and 20 patients were healthy, asymptomatic
leucine-rich repeat kinase 2 mutation carriers. We also included 35 patients with sporadic
PD (sPD) and 42 age-matched healthy controls. Levels of CSF α-synuclein oligomers
were significantly elevated in healthy asymptomatic individuals carrying leucine-rich repeat
kinase 2 mutations (n = 20; P < 0.0079) and in sPD group (n = 35; P < 0.003) relative
to healthy controls. Increased α-synuclein oligomers in asymptomatic leucine-rich repeat
kinase 2 mutation carriers showed a sensitivity of 63.0% and a specificity of 74.0%, with
an area under the curve of 0.66, and a sensitivity of 65.0% and a specificity of 83.0%,
with an area under the curve of 0.74 for sPD cases. An inverse correlation between CSF
levels of α- synuclein oligomers and disease severity and duration was observed. Our study
suggests that quantification of α-synuclein oligomers in CSF has potential value as a tool
for PD diagnosis and presymptomatic screening of high-risk individuals.
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INTRODUCTION
Parkinson’s disease (PD) is the most common age-related move-
ment disorder and the second most common neurodegenerative
disorder after Alzheimer’s disease. The earliest clinical features
of PD are typically retrospective and not specific, and they may
include depression, hyposmia, constipation, and sleep disorders.
At least 70% of the neurons in the substantia nigra (SN) are lost
prior to the appearance of any major motor symptoms (Schapira,
1999). The main motor symptoms, including resting tremor,
rigidity, bradykinesia, and postural instability, are collectively
known as parkinsonism. Currently, PD is clinically diagnosed and
clinical trials of disease-modifying drugs are initiated only after
most of the vulnerable dopaminergic neurons in the SN have
already been lost. Individuals at risk for PD with less complete loss
of dopaminergic neurons may be more responsive to and ben-
efit most from neuroprotective therapies. Therefore, identifying
biomarkers for early diagnosis may facilitate the development of
novel treatments designed to slow disease progression. Further-
more, such findings may help to elucidate the pathophysiology of
PD. Most PD cases are sporadic (sPD) (i.e., idiopathic; attributed
to unknown causes). However, some atypical cases involve genetic
susceptibility (Singleton et al., 2013). Over the last two decades,
several genetic causes of PD have been identified. At present,
5–10% of all PD cases can be traced to a known genetic cause that
is either monogenic or related to a combination of susceptibility
factors (Singleton et al., 2013). Mutations in the gene encoding
α-synuclein (α-syn) (SNCA) were the first genetic factors to be
linked to familial PD (Polymeropoulos et al., 1997; Krüger et al.,
1998; Singleton et al., 2003). Although SNCA mutations rarely
cause late-onset familial PD, SNCA is still of great importance
to PD etiology, as abnormal aggregation of α-syn in the brain
is also found in neuropathological lesions (Lewy bodies (LBs);
Spillantini et al., 1997). However, it has been previously shown
that α-syn is normally released by neuronal cells and present in the
cerebrospinal fluid (CSF) and peripheral plasma (El-Agnaf et al.,
2003) Recent studies have demonstrated that oligomeric forms of
α-syn are neurotoxic species in vitro and in vivo, whereas amyloid
fibrils may not be directly toxic (Winner et al., 2011). Gene
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mutations in leucine-rich repeat kinase 2 (LRRK2) are the second
most common cause of autosomal dominant PD and cause 2–
5% of familial PD. The most common point mutation, G2019S,
has been shown to be involved in 5–6% of autosomal dominant
PD cases (Di Fonzo et al., 2005; Nichols et al., 2005; Dächsel
and Farrer, 2010) and 1–2% of sPD cases (Gilks et al., 2005).
Patients with late-onset monogenic forms of PD may demonstrate
subtle signs or symptoms several years before they suffer from any
motor symptoms (Sossi et al., 2010; Johansen et al., 2011; Ruiz-
Martínez et al., 2011). Similarly, recent positron emission tomog-
raphy (PET) studies have confirmed dopaminergic dysfunction
in asymptomatic LRRK2 mutation carriers (Nandhagopal et al.,
2008). Therefore, these carriers are an ideal population for iden-
tifying novel biomarkers for the early diagnosis of PD. We and
other groups recently reported elevated levels of α-syn oligomers
(o-α-syn) and an increased o-α-syn/total-α-syn (t-α-syn) ratio in
CSF from PD patients relative to controls (Tokuda et al., 2010;
Park et al., 2011; Sierks et al., 2011; Parnetti et al., 2014a,b). These
findings suggest that CSF α-syn oligomers could be a potentially
useful biomarker for diagnosis and possible early detection of PD.
We therefore explored the potential use of o-α-syn as an early
biomarker for PD in CSF from asymptomatic LRRK2 mutation
carriers and symptomatic LRRK2 PD patients relative to sPD
patients and healthy age-matched controls.
MATERIALS AND METHODS
PATIENT POPULATION AND CLINICAL METHODS
In total, 33 Norwegian individuals from 12 different families with
mutant LRRK2 were assessed in this study. Thirteen patients
were clinically diagnosed with PD and 20 patients were healthy,
asymptomatic LRRK2 mutation carriers. These families have been
extensively described in previous report (Aasly et al., 2005, 2010;
Johansen et al., 2010). In addition, 35 patients with sPD and 42
age-matched healthy controls were also recruited for this study
from St. Olav’s Hospital at the University Hospital of Trond-
heim in Norway. Parkinson’s disease was diagnosed according to
established diagnostic criteria (Gelb vs. UK Parkinson’s Disease
Society). Disease severity was defined according to the Hoehn and
Yahr scale (H&Y). All patients with sPD were screened and tested
negative for known LRRK2 mutations. Patients with age at onset
≤50 years also tested negative for known pathogenic mutations
in Parkin and PINK1. All family members were screened for
clinical signs of PD and found to be asymptomatic, although a few
had mild pre-motor signs with an increased Unified Parkinson’s
Disease Rating Scale (UPDRS) score (Johansen et al., 2011).
The LRRK2-mutant PD patients were on levodopa, and some
were taking other dopamine agonists and monoamine oxidase-B
(MAO-B) inhibitors. The mean levodopa-equivalent dose in the
LRRK2-mutant PD group varied between 300 and 1800 mg, with
a mean of 580± 422 mg, and the mean levodopa-equivalent dose
in the sPD group was 300 to 1500 mg, with a mean of 628 ±
387 mg.
All individuals underwent lumbar puncture between 08:00 am
and 10:00 am following overnight fasting. A small sample of CSF
was sent for routine analysis, and then 18 to 22 ml was sampled
and frozen in 15 aliquots of 1.2–1.5 ml each within 15 min of
completion of the lumbar puncture. The aliquots were stored at
−80◦C until further analysis. All patients gave signed, informed
consent, and the study was approved by the Regional Committee
for Medical and Health Research Ethics.
SIZE EXCLUSION CHROMATOGRAPHY (SEC) FOR SEPARATING α-syn
MONOMERS AND OLIGOMERS
Size Exclusion Chromatography was carried out using an AKTA
FPLC system (GE Healthcare-Sweden) and a superdex 200 col-
umn at 4◦C. Concentrated 0.5 ml of CSF were loaded onto
the column and eluted with PBS (pH 7.4) at a flow rate of
0.1 ml/min (0.5 ml/fraction). The elution of α-syn was monitored
at absorbance wavelengths of 215 nm. Fractions of 1 ml were
collected, concentrated to 100 µl using a speed vac, and analyzed
by the western blotting for the presence of α-syn. To determine
the elution time of monomeric and oligomeric α-syn, molecu-
lar weight standards (Thyroglobulin 669 kDa, ferritin 440 kDa,
aldolase 171 kDa, abmumin 68 kDa and chymotrypsinogenA
25 kDa), fresh α-syn solution and aged α-syn solution were
co-injected into the column and eluted at the same conditions
mentioned above.
SODIUM DODECYL SULFATE–POLYACRYLAMIDE GEL
ELECTROPHORESIS (SDS–NuPAGE) AND IMMUNOBLOTTING
The CSF fractions were separated on NuPAGE Bis–Tris 4–12%,
1 mm gels (Invitrogen Ltd., Paisley, UK) and then transferred to
nitrocellulose membranes (0.45 µm) at 30 V, 125 mA for 45 min
(Invitrogen Ltd., Paisley, UK). Membranes were boiled for 5 min
in PBS then blocked for 1 h with 5% marvel dried skimmed
milk and dissolved in PBS–Tween 20 (0.05%) (PBST). The mem-
branes were probed overnight at 4◦C anti-α-syn (211) mouse
monoclonal antibody to α-syn (aa 121–125). The membranes
were washed several times with PBST followed by incubation
with horseradish peroxidase (HRP)-conjugated goat anti-mouse
(Dako Ltd., Ely, UK), for 60 min. The membranes were again
washed several times with PBST. The protein bands were visu-
alized using ECL reagents (Pierce, USA) as described by the
manufacturer.
IMMUNOASSAYS FOR TOTAL AND OLIGOMERIC α-SYNUCLEIN IN CSF
A sandwich enzyme-linked immunosorbent assay (ELISA) meth-
ods were employed to measure total or oligomeric α-syn levels in
CSF samples as described previously (Tokuda et al., 2010).
STATISTICAL ANALYSIS
Differences between groups were compared using a Mann-
Whitney U test. Significance was defined as P < 0.05. Corre-
lational analysis was conducted by Pearson simple correlation.
The receiver operating characteristic (ROC) was analyzed to
assess the most appropriate cut-off values for the level of CSF
α-syn oligomer and the oligomers/total-α-syn ratio in the CSF
to distinguish between groups. All analyses were conducted using
GraphPad Prism software (GraphPad Prism Version 4.0, Graph-
Pad software, San Diego, CA).
RESULTS
PATIENT POPULATION AND DEMOGRAPHICS
In total, 33 Norwegian individuals from 12 different LRRK2 fam-
ilies were investigated in the present study. Thirteen individuals
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with LRRK2 point mutations had developed symptomatic PD,
including 11 males who were carrying the most common LRRK2
point mutation, G2019S, and two females who were carrying a
different LRRK2 point mutation, N1437H. The 13 individuals had
a mean age of 64.0 years ± 13.3 years. In contrast, 20 individuals
were healthy asymptomatic LRRK2 mutation carriers [G2019S
(n = 16) and N1437H (n = 4)]. These 20 individuals had a mean
age of 55.4 years ± 15 years. None of the healthy asymptomatic
LRRK2 mutation carriers (LRRK2-H) had any complaints of a
movement disorder. Some were receiving medication for diabetes
mellitus, mild hypertension, and other minor health problems.
In addition, 35 patients with sPD and 42 age-matched healthy
controls were also included in this study. No significant differ-
ence was noticed in disease duration between symptomatic PD
patients with LRRK2 mutations (LRRK2-PD) and sPD patients.
Moreover, there was no difference between the groups with
regard to CSF levels of leukocytes or total protein, albumin,
and glucose levels, including plasma glucose levels. Controling
for age and gender did not significantly alter the results in any
case. A summary of the patient population employed in the
present study and the respective demographic details are shown
in Table 1.
LEVELS OF TOTAL α syn (t-α syn) IN CSF SAMPLES
To measure the total α-syn (t-α-syn) in CSF samples, we
recently optimized our original α-syn ELISA protocol using a
chemiluminescence-based read-out arm for HRP-labeled anti-
body detection (Tokuda et al., 2010). We demonstrated that our
optimized protocol yielded excellent performance with regard to
both specificity and sensitivity. Using this system, an increase of
approximately 100-fold in the detection of recombinant α-syn
was recorded, ranging from 0.010 to >500 ng/ml (Tokuda et al.,
2010).
As illustrated in Figure 1, the concentration of t-α-syn var-
ied considerably among the four studied groups, although the
difference was not statistically significant. Lower mean con-
centrations of CSF t-α-syn were observed in patients with
sPD (mean ± SEM = 22.81 ± 4.198 ng/ml, n = 35),
LRRK2-PD (mean ± SEM = 20.54 ± 3.139 ng/ml, n = 13),
and LRRK2-H (mean ± SEM = 17.84 ± 2.569 ng/ml,
n = 20) than in age-matched controls (mean ± SEM =
24.74 ± 4.470 ng/ml, n = 42) (P = 0.7001, Mann-Whitney
U-test).
CSF α syn OLIGOMERS (o-α syn) LEVELS
After measuring the total α-syn in CSF samples from our
cohort, we then measured the levels of CSF α-syn oligomers (o-
α-syn) in the same samples. For such measurements, we used
an ELISA system for α-syn oligomers that specifically detects
soluble oligomers without detecting monomeric forms of α-syn
(El-Agnaf et al., 2006). Because α-syn oligomers represent a
small fraction of the total α-syn in CSF, for this assay we also
used a chemiluminescence-based read-out arm to allow detec-
tion of low levels of CSF α-syn oligomers. The ELISA protocol
was based on a conventional sandwich system in which mAb
211 was used to capture α-syn, followed by detection with a
biotinylated form of 211. Subsequently, the biotinylated mAb was
detected with ExtrAvidin-HRP, followed by a chemiluminescent
substrate. In this assay, no signal is detected for monomeric
α-syn, as the capture mAb occupies the only available antibody
binding site on the protein. In contrast, multiple mAb bind-
ing sites are available in the case of oligomeric forms of α-
synuclein, thus permitting both capture and detection (El-Agnaf
et al., 2006). This assay has been extensively characterized and
yields excellent performance in both specificity and sensitivity
(Tokuda et al., 2010). In order to investigate the size of α-syn
oligomers detected by our ELISA in CSF, recently we used SEC
to fractionate fresh CSF samples from those PD patients that
gave a robust signal in our ELISA. The western blot revealed
immunoreactive material with an elution peak in SEC fractions
corresponding to MW of 70 and 170 kDa which belong to
α-syn monomers and dimmers respectively. However, much of
the immunereactive material was eluted at the void volume,
which indicated a MW of >670 kDa (Figure 2A). These SEC
fractionation results support the notion that the CSF from PD
patients mainly contain HMW α-syn oligomers, since most of the
protein material detected by the ELISA has a MW >760 kDa.
Experiments are in progress in our laboratory to further char-
acterize and analyze the structure and nature of the oligomeric
species of α-syn and to discern any modifications of α-syn
detected by the ELISA (i.e., nitrated, phosphorylated, etc.). This
information will be useful in order to improve both the sensitivity
and selectivity for α-syn protein species in our future ELISA
variants.
A scatter plot representing the CSF levels of o-α-syn for each
patient in the four groups is shown in Figure 2B; the level
of o-α-syn is given as the chemiluminescence signal intensity
Table 1 | Details of patient population employed in the present study and the demographics.
Groups Symptomatic PD due Asymptomatic LRRK2 Sporadic PD Healthy
to LRRK2 mutations mutation carriers controls
Number of individuals 13 20 35 42
Gender (M/F) 11/2 11/9 23/2 14/21
Age range (y) 43–87 26–76 38–71 37–74
Mean Age (y) 64 ± 13.3 55.4 ± 15 54 ± 15 59 ± 10
Levodopa equivalents 580 ± 422 mg NA 628 ± 387 mg NA
H-Y grade 2.7 ± 0.7 NA 2.28 ± 0.6 NA
Disease duration (months) 24–330 NA 12–300 NA
PD = Parkinson’s disease; y = years; M = male; F = female; H-Y grade = Hoehn-Yahr grade.
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FIGURE 1 | Levels of t-α-syn (in ng/ml) in CSF from healthy controls
(HC), sporadic PD patients (sPD), symptomatic PD patients with LRRK2
mutations (LRRK2-PD), and healthy asymptomatic LRRK2 mutation
carriers (LRRK2-H). Values are expressed as the mean ± standard
deviation.
(relative luminescence units/second [RLU/s]). The level of CSF
o-α-syn was significantly higher by 4-fold in the sPD group
(mean ± SEM = 80,186 ± 23,861, n = 35) relative to the
healthy age-matched control group (mean ± SEM = 17,117 ±
2943, n = 42) (P < 0.01, Mann-Whitney U test). Significantly
higher levels of CSF o-α-syn (approximately 2-fold higher) were
also detected in LRRK2-H (mean ± SEM = 38,754 ± 12,514,
n = 20) relative to the control group (mean ± SEM = 17,117 ±
2,943, n = 42) (P < 0.01, Mann-Whitney U test). Unexpectedly,
LRRK2-PD patients (mean ± SEM = 24,510 ± 7,161, n = 13)
did not show any significant difference in the level of o-α-syn
in the CSF relative to the healthy control group (P = 0.1910,
Mann-Whitney U test), possibly because of the low number of
individuals in this group (n = 13 vs. n = 42). Furthermore, we
observed a significant inverse correlation (Spearman r = −0.49,
P < 0.05) between the severity of the disease and the level of o-
α-syn in the CSF of sPD patients using H&Y grading (Table 2).
However, no significant correlation (Spearman r = −0.5391, P
= 0.09) between H&Y grading and the levels of o-α-syn in the
CSF of LRRK2-PD patients was observed (Table 2). Interestingly,
when sPD and LRRK2-PD cases were combined together, more
significant and stronger inverse correlation was noted (Spearman
r = −0.6, P = 0.0004, Table 2). Whereas, CSF t-α-syn levels did
not correlate with H&Y levels. In parallel, statistically significant
inverse correlation between CSF o-α-syn and disease duration was
also observed in sPD group (Spearman r = −0.45, P < 0.05), but
CSF o-α-syn did not correlate with disease duration in LRRK2-
PD group. Whereas, we observed significant negative correlation
between CSF o-α-syn levels and disease duration when the sPD
and LRRK2-PD groups were combined together (Spearman r =
−0.5, P = 0.002, testable 2). In contrast, CSF o-α-syn levels did
not correlate with UPDRS scores within any of the groups (data
not shown). In addition, no correlation was observed between
the level of o-α-syn in the CSF and the age of the patients
(data not shown).
The measurement of both total and oligomeric α-syn in
RLU/s allowed us to calculate the ratio of o-α-syn to t-α-syn
(o-α-syn/t-α-syn ratio [%]) in the CSF of each patient, as
shown in Figure 3. This ratio was found to be significantly
higher in the sPD group (mean ± SEM = 71.59 ± 12.76,
FIGURE 2 | (A) Size exclusion chromatographic analysis of α-syn oligomers in
CSF. Five mls of CSF from a PD patient concentrated to 0.5 ml, was
fractionated on a superdex 200 SE column. The elution volume for
monomeric (M) α-syn was determined by fresh recombinant α-syn solution
and molecular weight standard, and was eluted in a peak corresponding to
column volume of 13–14 ml (kDa ∼68), while dimeric (D) α-syn was eluted in
a peak corresponding to column volume of approximately 12 ml (kDa ∼170).
High molecular weight oligomeric α-syn was determined by aged
recombinant α-syn solution and molecular weight standard, and was eluted in
a peak corresponding to column volume of approximately 9 ml (670 kDa). The
void volume (V) corresponds to MW >670 kDa. The fractions of 1 ml which
correspond to the oligomeric and monomeric α-syn peaks were separately
collected, concentrated to 100 µl using a speed vac, and then analyzed by
western blotting for the presence of α-syn using anti-α-syn (211) antibody
(1:1000). (B) Scatter plot representing individual values of the levels of o-α-syn
(in relative luminescence units/second [RLU/s]) in CSF from healthy controls
(HC; open circles), symptomatic PD patients with LRRK2 point mutations
(LRRK2-PD; open triangles), patients with (sPD; inverted open triangles), and
healthy asymptomatic LRRK2 mutation carriers (LRRK2-H; open squares).
Each bar represents the mean value.
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Table 2 | Spearman correlations between CSF α-syn species, disease duration (months), and Hoehn and Yahr stage in sPD and LRRK2-PD.
Disease duration (months) Hoehn and Yahr stage
Case sPD LRRK2-PD sPD+LRRK2-PD sPD LRRK2-PD sPD+LRRK2-PD
t-α-syn NS NS NS NS NS NS
o-α-syn −0.45* NS −0.5** −0.5* NS −0.6***
* P < 0.05, ** P < 0.01, *** P < 0.001, NS = Not-Significant.
n = 35) (P < 0.001, Mann-Whitney U test) and LRRK2-
H group (mean ± SEM = 103.1 ± 47.91, n = 20) (P <
0.05, Mann-Whitney U test) than in the healthy control group
(mean ± SEM = 40.97 ± 21.62, n = 42). No significant dif-
ference in the ratio of o-α-syn to t-α-syn was found in the
LRRK2-PD relative to controls (mean ± SEM = 24.08 ± 7.359,
n = 13) (P = 0.5297, Mann-Whitney U test), possibly because
of the small number of individuals in this group (n = 13 vs.
n = 42).
Figure 4 shows the ROC curve for CSF o-α-syn and the ratio
of o-α-syn to t-α-syn in the discrimination of PD patients from
controls. The ROC curve indicates that cutoff values of 31,671.9
RLU/s for CSF o-α-syn and 24.1% for the CSF o-α-syn to t-α-syn
ratio were the most reliable measures to distinguish sPD from
controls. Detection of CSF α-syn oligomers yielded a sensitivity
of 65% (95% CI, 53–77%) and a specificity of 83% (95% CI, 73–
93%), with an area under the curve (AUC) of 0.74 (95% CI, 0.60–
0.88). The o-α-syn to t-α-syn ratio yielded a sensitivity of 73%
(95% CI, 62 to 84%) and a specificity of 77% (95% CI, 0.66–0.88),
with an AUC of 0.79 (95% CI, 0.67–0.91). Furthermore, the ROC
analysis demonstrated that cutoff values of 20,566 RLU/s for CSF
o-α-syn and 9.4% for the CSF o-α-syn to t-α-syn ratio provided
the most reliable measure to differentiate LRRK2-H from healthy
controls. The sensitivity and specificity of CSF o-α-syn to predict
LRRK2-H were 63% (95% CI, 0.50–0.76) and 74% (95% CI, 0.62–
0.86), respectively, with an AUC of 0.66 (95% CI, 0.50 to 0.82).
The sensitivity of the CSF oligomer to t-α-syn ratio was 53% (95%
CI, 39–67%), and the specificity was 81% (95% CI, 0.70–0.92)
with an AUC of 0.64 (95% CI, 0.47–0.80).
DISCUSSION
Currently the diagnosis of PD is based mainly on clinical symp-
toms. However, differential diagnosis from other parkinsonisms
can be difficult and can lead to misdiagnosis. To date, no simple
laboratory biomarker is available to detect individuals at risk
for PD before most of their dopaminergic neurons have been
lost.
Numerous studies have suggested that neuronal cell death may
result from the formation of oligomeric species of α-syn in the
brain (Irvine et al., 2008). It has been previously shown that
levels of soluble o-α-syn are elevated in brain homogenates from
patients with PD and DLB relative to normal brains (Paleologou
et al., 2009). Recently, it has been reported by us and others
significant higher levels of CSF o-α-syn in PD patients com-
pared to age-matched controls (Tokuda et al., 2010; Park et al.,
2011; Sierks et al., 2011; Parnetti et al., 2014a,b). Levels of o-
α-syn and the o-α-syn to t-α-syn ratio have also been shown
to be higher in patients with mild PD (H&Y grades 1 and
2) and patients with early PD (within 24 months after onset)
relative to a control group (Tokuda et al., 2010). The aim of this
study was to determine whether o-α-syn is suitable biomarker
for detecting PD at the early stages of the disease. Recently,
abnormal PET changes and olfactory dysfunction were reported
in LRRK2-H (Nandhagopal et al., 2008; Ruiz-Martínez et al.,
2011; Saunders-Pullman et al., 2011). Therefore, healthy family
members with LRRK2 mutations are an excellent population for
validating surrogate biomarkers for early stages of PD. A recent
study reported a lack of a statistically significant relationship
between PET scan evidence of lost striatal dopaminergic func-
tion and the levels of DJ-1 and t-α-syn in CSF from LRRK-H
or LRRK-PD cases (Shi et al., 2012). In the present study, we
assessed the levels of CSF o-α-syn in symptomatic and asymp-
tomatic LRRK2 mutation carriers and in sPD cases. We observed
significantly elevated levels of CSF α-syn oligomers in LRRK-
H relative to healthy controls (Figure 2B), which suggests that
the formation of o-α-syn in the brain commences several years
before LRRK2 mutation carriers experience any motor symptoms
of PD. Furthermore, we also observed significantly higher o-
α-syn levels in the CSF of sPD cases relative to healthy age-
matched controls (Figure 2B), which confirms previous find-
ings (Tokuda et al., 2010; Park et al., 2011; Sierks et al., 2011).
Unexpectedly, we did not observe any significant difference in
the CSF levels of o-α-syn between LRRK-PD patients and healthy
controls, possibly because of the low number of individuals in
this group (n = 13 vs. n = 42). However, we noticed in this
group that patients with mild PD (H&Y grade ≤2) showed
high levels of CSF o-α-syn similar to those of sPD patients.
Conversely, patients with higher H&Y grades (>2) had lower
levels of α-syn oligomers, which supports the hypothesis that
at the early stages of the disease, high levels of toxic o-α-syn
accumulate in the brain. In support of this notion, we also found
that levels of CSF o-α-syn were inversely correlated with disease
duration and H&Y grade in LRRK2-PD and sPD cases, which
confirms that CSF levels of o-α-syn decrease with increasing PD
severity (Table 2). Thus, we speculate that o-α-syn is formed
during the early stages of the disease prior to any major clinical
manifestation.
Unified Parkinson’s Disease Rating Scale is the most com-
monly used clinical scale to provide an efficient and flexible assess-
ment of motor performance in PD patients and to monitor the
degree of resultant disability. However, thus far, no strong linear
relationship has been established between UPDRS scores and the
progressive nigrostriatal degeneration in PD, which may underlie
the absence of a correlation between CSF α-syn levels and UPDRS
scores. Cerebrospinal fluid biomarkers mirror changes within the
brain as an entire unit, whereas UPDRS scores primarily reflect
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FIGURE 3 | Scatter plot presenting individual values for the ratio of
o-α-syn to t-α-syn (o-α-syn/t-α-syn ratio,%) in CSF from healthy
controls (HC; open circles), symptomatic PD patients with LRRK2
point mutations (LRRK2-PD; open triangles), patients with (sPD;
inverted open triangles), and healthy asymptomatic LRRK2
mutation carriers (LRRK2-H; open squares). Each bar represents the
mean value. The P value for each regression line is shown in each
subfigure.
FIGURE 4 | Use of receiver operating characteristic (ROC) curves for the levels of CSF t-α-syn, o-α-syn and o-α-syn/t-α-syn ratio (%) to discriminate
between (sPD) patients and controls (A), and healthy asymptomatic LRRK2 mutation carriers (LRRK2-H) patients and controls (B).
changes in the nigrostriatal dopaminergic system. In addition,
compensatory responses in PD may further confound the cor-
relation between CSF biomarkers and the severity of PD motor
symptoms (Shi et al., 2011). Moreover, DA replacement therapy
provided to PD patients enhances motor function while showing
little or no effect on CSF protein concentrations (Hong et al.,
2010; Shi et al., 2011).
It has been recently reported that the most common
LRRK2 point mutation, G2019S, initiates and enhances the
formation of α-syn aggregates (Lin et al., 2009), possibly
by impairing degradation pathways such as the autophagy-
lysosomal pathway (Ferree et al., 2012; Tong et al., 2012).
Overall, the potential interactions of LRRK2 and α-syn have
not been clearly established. Although most LRRK2-related PD
cases are pathologically and clinically undistinguishable from
sPD, LRRK2 mutation carriers exhibit considerable clinical and
pathological variability (Wider et al., 2010). Our results sup-
port the hypothesis that mutations in LRRK2 may lead to
the formation of the toxic oligomeric forms of α-syn criti-
cal for the pathogenesis of PD. However, our findings need
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to be confirmed in prospectively planned, independent cohort,
particularly in samples where PD has been longitudinally
assessed such as the ongoing Parkinson’s Progression Markers
Initiative.
In conclusion, our current pilot study suggests for the first
time that quantification of o-α-syn in CSF has strong potential
value as a tool for PD diagnosis and presymptomatic screening
of high-risk individuals who are good candidates for clinical
trials. However, large-scale, prospective, and well-controlled stud-
ies, especially those that include subjects at genetic risk, are
necessary to validate the use of CSF o-α-syn as a biomarker
for PD.
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